Análise para o tratamento da Dermatite Atópica: uma abordagem sobre a eficácia e segurança de novas terapias
DOI:
https://doi.org/10.36557/2674-8169.2026v8n3p1817-1847Palavras-chave:
Eczema atópico, Anticorpos monoclonais, Imunossupressores, MétodosResumo
A dermatite atópica (DA), também conhecida como eczema atópico, é uma doença inflamatória crônica, frequente desde a infância e capaz de afetar de forma relevante a qualidade de vida dos pacientes acometidos. Nos últimos anos, o tratamento tem avançado por meio do desenvolvimento de novas terapias direcionadas ao controle da inflamação e melhora dos sintomas clínicos. Após análise, a presente revisão reuniu 64 artigos publicados entre 2019 e 2025 nas principais bases de dados disponíveis, como Scielo, Google acadêmico e PubMed, buscando comparar os principais medicamentos em uso, entre eles imunobiológicos, inibidores de JAK e metotrexato em uso off-label. Os estudos envolveram pacientes com DA moderada a grave, de diferentes faixas etárias, incluindo desde crianças a idosos. Como resultados, o Dupilumabe se mantém como primeira opção, mais segura, eficaz e, por seu tempo de mercado, seus efeitos colaterais são amplamente conhecidos. Em paralelo, os inibidores da JAK, como Abrocitinibe e o Upadacitinibe, têm se destacado pelo início de ação mais rápido e resultados expressivos em curto prazo. O Tralokinumabe, voltado contra a IL-13, pode ser uma alternativa promissora nos próximos anos, embora as evidências sejam iniciais. Assim, embora o avanço científico tenha ampliado o leque de opções, a escolha do tratamento ideal deve ser individualizada, considerando eficácia, segurança, custos e o perfil de cada paciente. Ainda se faz necessário o desenvolvimento de pesquisas a longo prazo, capazes de confirmar a durabilidade dos resultados e o real impacto dessas terapias emergentes na vida de pessoas com tal patologia.
Downloads
Referências
AGUIAR, Mariana herculano. Relatório apresentado para a obtenção do grau de Mestre em Ciências Farmacêuticas. Hospital privado de gaia, Porto, ano 2022, v. 1, n. 1, p. 1 -61, 14 out. 2022.
AOKI, V. et al. Consensus on the therapeutic management of atopic dermatitis. Brazilian Society of Dermatology, [S. l.], ano 2019, n. 1, p. 1 - 9, 13 jan. 2019. DOI: http://dx.doi.org/10.1590/abd1806-4841.2019940210.
BAWANY, F. et al. Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. The journal of allergy and clinical immunology. In practice, v. 9, n. 4, p. 1488–1500, 1 abr. 2021.
BIEBER, T. et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. The New England Journal of Medicine, v. 384, n. 12, p. 1101–1112, 25 mar. 2021.
BLAUVELT, A. et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, v. 157, n. 9, p. 1047, 1 set. 2021.
BURMESTER, G. R. et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open, v. 9, n. 1, p. e002735, fev. 2023.
CARON, A. G. M. et al. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review. Journal of Dermatological Treatment, v. 35, n. 1, 20 dez. 2023.
CHOVATIYA, R.; PALLER, A. S. JAK inhibitors in the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology, v. 148, n. 4, p. 927–940, out. 2021.
CHU, A. W. L. et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. The Journal of Allergy and Clinical Immunology, v. 152, n. 6, 5 set. 2023.
DAVARI, D. R. et al. Current Perspectives on the Systemic Management of Atopic Dermatitis. Journal of Asthma and Allergy, v. Volume 14, p. 595–607, jun. 2021.
DELEURAN, M. et al. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta dermato-venereologica, v. 101, n. 7, p. adv00504, Autumn 2021.
FANG, Z. et al. Gut Microbiota, Probiotics, and Their Interactions in Prevention and Treatment of Atopic Dermatitis: A Review. Frontiers in Immunology, v. 12, 14 jul. 2021.
FAYE, O. et al. Validation of the Patient‐Oriented SCOR ing for Atopic Dermatitis tool for black skin. Journal of the European Academy of Dermatology and Venereology, v. 34, n. 4, p. 795–799, abr. 2020.
GHANNOUM, M. et al. Extracorporeal Treatment for Methotrexate Poisoning. Clinical Journal of the American Society of Nephrology, p. CJN.08030621, 2 mar. 2022.
GILBERTO et al. Dupilumab in pediatric atopic dermatitis: real-world evidence from two national centers. Portuguese Journal of Dermatology and Venereology, v. 82, n. 2, 12 mar. 2024.
GRAJALES, D. B. et al. Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD). Medicine in Drug Discovery, v. 20, p. 100161, 1 dez. 2023.
GRISTAN, Y. D.; PATEL, P.; MOOSAVI, L. Folinic Acid. StatPearls, 2024.
HANIFIN, J. M. et al. The Eczema Area and Severity Index—A Practical Guide. Dermatitis, v. 33, n. 3, p. 187–192, maio 2022.
KHADKA, V. D. et al. The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment. Frontiers in Cellular and Infection Microbiology, v. 11, n. 11, 24 set. 2021.
LEE, Y.-J. et al. Interactions between Malassezia and New Therapeutic Agents in Atopic Dermatitis Affecting Skin Barrier and Inflammation in Recombinant Human Epidermis Model. International journal of molecular sciences, v. 24, n. 7, p. 6171–6171, 24 mar. 2023.
MAKOWSKA, K. et al. Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. International Journal of Molecular Sciences, v. 24, n. 1, p. 781, 2 jan. 2023.
MEDINA-RODRIGUEZ, E. M.; BEUREL, E. Blood brain barrier and inflammation in depression. Neurobiology of Disease, v. 175, p. 105926, 1 dez. 2022.
MORENO, A.; RENERT-YUVAL, Y.; GUTTMAN-YASSKY, E. Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis. Expert Review of Clinical Pharmacology, v. 16, n. 2, p. 119–131, 27 jan. 2023.
MUZZOLON, M. et al. DERMATITE ATÓPICA E TRANSTORNOS MENTAIS: ASSOCIAÇÃO EM RELAÇÃO À GRAVIDADE DA DOENÇA. Revista Brasileira de Neurologia e Psiquiatria, v. 25, n. 1, 24 set. 2021.
NASCIMENTO, G. et al. Inhibidores de JAK en pacientes con dermatitis atópica: revisión sistemática sobre el uso de Abrocitinib. Revista Cubana de Reumatología, v. 25, n. 2, p. -, 2023.
ONG, Peck. Atopic dermatitis: Is innate or adaptive immunity in control? A clinical perspective. Frontiers immunology, [S. l.], ano 2022, v. 13, p. 1 - 9, 26 jul. 2022. DOI https://doi.org/10.3389/fimmu.2022.943640.
PALLER, A. S. et al. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis. Advances in Therapy, v. 41, n. 3, p. 1046–1061, 9 jan. 2024.
PALLER, A. S. et al. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatology, v. 159, n. 5, p. 526–535, 1 maio 2023.
PEREYRA-RODRIGUEZ, J.-J. et al. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Life, v. 11, n. 9, p. 927, 6 set. 2021.
PESSOA E COSTA, T. et al. Dupilumab Treatment in Atopic Dermatitis: Real-World Evidence from a Portuguese Tertiary Center. Journal of the Portuguese Society of Dermatology and Venereology, v. 79, n. 2, p. 113–116, 25 jun. 2021.
PETER et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). Journal of The American Academy of Dermatology, v. 89, n. 3, p. 478–485, 1 set. 2023.
PRADO, E. et al. Dermatite atópica grave: guia prático de tratamento da Associação Brasileira de Alergia e Imunologia e Sociedade Brasileira de Pediatria. Arquivos de Asmas Alergia e Imunologia, v. 6, n. 4, 2022.
RATCHATASWAN, T. et al. Biologics for treatment of atopic dermatitis: current status and future prospect. Journal of Allergy and Clinical Immunology: In Practice, v. 9, n. 3, p. 1053-1065, mar. 2021. DOI: https://doi.org/10.1016/j.jaip.2020.11.034
SAMORANO, L. P. et al. Methotrexate for refractory adult atopic dermatitis leads to alterations in cutaneous IL-31 and IL-31RA expression. Anais Brasileiros de Dermatologia, v. 99, n. 1, p. 72–79, 18 set. 2023.
SANDHU, J. K. et al. Association Between Atopic Dermatitis and Suicidality. JAMA Dermatology, v. 155, n. 2, p. 178, 1 fev. 2019.
SCHONMANN, Y. et al. Atopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study. The Journal of Allergy and Clinical Immunology. in Practice, v. 8, n. 1, p. 248-257.e16, 1 jan. 2020.
SEDEH, F. B. et al. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica, v. 102, p. adv00764, 24 ago. 2022.
SHI, V. Y. et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). Journal of the American Academy of Dermatology, v. 87, n. 2, p. 351–358, ago. 2022.
SIEGFRIED, E. C. et al. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. American Journal of Clinical Dermatology, v. 22, n. 2, p. 243–255, mar. 2021.
SILVERBERG, J. I. et al. Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis. Journal of the European Academy of Dermatology and Venereology, v. 35, n. 9, p. 1797–1810, 12 jun. 2021.
SILVERBERG, J. I. et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. v. 149, n. 3, p. 977-987.e14, 14 ago. 2021.
SIMPSON, E. L. et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, v. 396, n. 10246, p. 255–266, jul. 2020.
SIMPSON, E. L. et al. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. American Journal of Clinical Dermatology, v. 24, n. 4, p. 609–621, 22 maio 2023.
SIMPSON, E. L. et al. Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials*. British Journal of Dermatology, v. 187, n. 6, p. 888–899, 26 out. 2022.
SROKA-TOMASZEWSKA, J.; TRZECIAK, M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. International Journal of Molecular Sciences, v. 22, n. 8, 16 abr. 2021.
TAVARES, F. et al. O impacto da Dermatite Atópica na saúde mental da população pediátrica: Uma revisão integrativa. Research Society and Development, v. 13, n. 7, p. e9613746379-e9613746379, 19 jul. 2024.
TORRES, T. et al. Update on Atopic Dermatitis. Acta Médica Portuguesa, v. 32, n. 9, p. 606, 2 set. 2019.
VERBERNE, E. A. et al. “Fetal methotrexate syndrome: A systematic review of case reports.” Reproductive toxicology (Elmsford, N.Y.) vol. 87 (2019): 125-139. doi:10.1016/j.reprotox.2019.05.066
WOLLENBERG, A. et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology, v. 184, n. 3, p. 437–449, 30 dez. 2020.
YIM, H. J.; JEAN, T.; ONG, P. Y. Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis. Current allergy and asthma reports, 18 abr. 2024.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Lavínia Kobayashi Grigoletto, Gabriel Ourique Balbé, Emilene Dias Fiuza Ferreira, Letícia de Souza Pilan, Rômulo Lourenço Séleri
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.
